Dr. Min Cui
Founder and Managing Director, Decheng Capital
At Decheng Capital, Dr. Cui has been focusing on partnerships with entrepreneurs and building biotechnology and medical technology companies in China and US. He is currently a board member of Alpine Immune Sciences (NASDAQ: ALPN), Ariagen, Bioheng, CardiMED, Cue Health (NASDAQ: HLTH), EpimAb Biotherapeutics, GeneMDx, Ketai Medical, Mammoth Biosciences and Shape Therapeutics. He previously served on the boards of 3SBio (HK Stock Exchange: 1530), ARMO BioSciences (acquired by Eli Lilly), China Biologic Products (NASDAQ: CBPO), Cirina (acquired by GRAIL), Epizyme (NASDAQ: EPZM), GeneWEAVE Biosciences (acquired by Roche), GenturaDx (acquired by Luminex), GRAIL (acquired by Illumina), Ion Torrent Systems (acquired by Life Technologies), Sino Medical (688108.CH) and Velos Biopharma (acquired by Merck). Prior to founding Decheng Capital in 2011, Dr. Cui was an Investment Partner at Bay City Capital, a leading international life science venture capital firm in San Francisco. At Bay City, he led investment opportunities in US as well as all its initiatives in China. Dr. Cui was previously Director of Strategic Investment for the Southern Research Institute, an organization that discovered and developed six anti-cancer drugs that approved by the US Food and Drug Administration. Prior to that, Dr. Cui co-founded Pan Pacific Pharmaceuticals and Hucon Biopharmaceuticals, where he led efforts in discovery and development of several key technologies in the fields of oncology, cardiology, infectious and inflammatory diseases. Dr. Cui received his PhD in Cancer Biology from Stanford University and his BS and MS in Molecular Biology from Peking University. Dr. Cui was also a co-founder of CNetwork, a San Francisco based non-profit organization dedicated to serving Chinese communities in North America.